Houston Methodist. Leading Medicine.
Houston Methodist. Leading Medicine

Methodist J.C. Walter Jr. Transplant Center - Houston, TX

Dr. R. Mark Ghobrial

Total: 8

  1. Pretransplant variables associated with quality of life in liver transplant recipients.
    • Saab S, Ibrahim AB, Surti B, Durazo F, Han S, Yersiz H, Farmer DG, Ghobrial RM, Goldstein LI, Tong MJ, Busuttil RW.
    • Liver Int. 2008 Sep;28(8):1087-94. Epub 2008 Jul 25.

  2. Does race influence outcomes after primary liver transplantation? A 23-year experience with 2,700 patients.
    • Hong JC, Kosari K, Benjamin E, Duffy JP, Ghobrial RM, Farmer DG, Yersiz H, Xu J, Hiatt JR, Busuttil RW.
    • J Am Coll Surg. 2008 May;206(5):1009-16; discussion 1016-8. Epub 2008 Mar 17.

  3. Recurrence of hepatocellular carcinoma following liver transplantation: a review of preoperative and postoperative prognostic indicators.
    • Zimmerman MA, Ghobrial RM, Tong MJ, Hiatt JR, Cameron AM, Hong J, Busuttil RW.
    • Arch Surg. 2008 Feb;143(2):182-8; discussion 188. Review.

  4. Effectiveness and Tolerability of Sirolimus in Liver Transplantation – Novartis

  5. Ghobrial RM, Freise CE, Trotter JF, Tong L, Ojo AO, Fair JH, Fisher RA, Edmond JC, Koffron AJ, Pruett TL, Olthoff KM. Donor morbidity after living donation for liver transplantation. Gastroenterology 2008. (In print)

  6. Holt CD, McDiarmid SV, Ghobrial RM, Farmer DG, Ingle G, Dawson III S, Chen P, Busuttil RW. Efficacy and safety of low-dose tacrolimus and mycophenolate mofetil in OLT recipients. Transplantation. (In preparation)

  7. Ghobrial RM, Punch JD, Pinson CW, Dostal J, Carrier D. Impact of liver transplantation of patients with high disease severity on health care resources: University Healthsystem Consortium (UHC) Benchmarking Project. (In preparation)

  8. Gordon Burrough S, Hong J, Uchiyama K, Datta S, Farmer DG, Cholakian A, Busuttil RW, Ghobrial RM. The Effect of Immunosuppression on Outcomes of ABO-Incompatible Liver Transplantation in the Modern Era. (submitted)